PPD Snaps Up Patient Recruitment Specialist Acurian

By Zachary Brennan

- Last updated on GMT

PPD Snaps Up Patient Recruitment Specialist Acurian
CRO Pharmaceutical Product Development (PPD) on Tuesday announced it has acquired Acurian to help build its clinical trial patient enrollment and retention tools. 

Financial details of the deal were not disclosed and Horsham, Pennsylvania-based Acurian will continue to operate under its own name and as a business unit of North Carolina’s PPD. The existing management team and Acurian CEO Rick Malcolm will remain in their positions.

At this time, the acquisition is not expected to change employment levels at Acurian or PPD​,” William Sharbaugh, COO of PPD, told Outsourcing-Pharma.com. “This investment in Acurian will enable us to provide our clients industry-leading services that accelerate patient enrollment and support their strategies for data-driven feasibility, site selection and enrollment delivery​.”

Acurian helps sponsors manage the patient recruitment cycle through proprietary and predictive software analytics.

PPD and Acurian both serve many large- and mid-sized pharma companies, and we work with a number of the same companies​,” Sharbaugh said, noting both companies are restricted in how much they can discuss on specific clients.

Acurian, which has operated for 15 years, last month launched clinical trial enrollment reports with cost analyses for over 30 therapeutic areas. The analyses offer insight into the budget implications for specialty recruitment services when compared to adding trial sites and/or time.

Acurian’s expertise spans multiple therapeutic areas, aligning with PPD's broad therapeutic area expertise​,” Sharbaugh said.

Acquisition Fever

PPD’s acquisition of Acurian is the latest in a string of M&A this summer that is seeing the CRO industry consolidate further, as experts predicted in June.

Since those predictions were made, private equity firm KKR purchased PRA​ for about $1.3B, acquired RPS​, and then merged PRA and RPS​.

Quintiles, the world’s largest CRO, also jumped into the M&A game earlier this month when it purchased Novella Clinical​.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars